Alpha Cognition: Focused on Neurodegenerative Diseases
Alpha Cognition is a clinical-stage, biopharmaceutical company. Their main focus is to develop treatments for neurodegenerative diseases, like Alzheim …
Dedicated to developing treatments for neurodegenerative diseases
Alpha Cognition is a clinical-stage, biopharmaceutical company. Their main focus is to develop treatments for neurodegenerative diseases, like Alzheimer's, Dementia, and Amyotrophic Lateral Sclerosis (ALS).
About ALPHA-1062
ALPHA-1062 is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. Furthermore, it is a prodrug of an approved AChEl, galantamine.
CEO, Michael McFadden says, "It will be one of the first innovations, if approved, in Alzheimer's in over a decade."
Additionally, ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. Moreover, it is in preclinical development for the treatment of ALS. Not to mention, ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.
For more information on Alpha Cognition (TSX.V: ACOG, OTCQB: ACOGF) please click the investor request info button.
Latest Articles
Hot Companies
You might also like
Volta Metals: Powering Tomorrow with Ontario’s Critical Minerals
As global demand for critical minerals surges, Volta Metals is strategically positioned in Northwestern Ontario, exploring lithium and rare metals in proximity to infrastructure and clean energy sources.
.png)
